Podcast Authority
Beta
Podcast Overview
<p>Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.</p>
Language
🇺🇲
Publishing Since
10/20/2024
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Recommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Hormone Insight
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
June 28, 2026
STEP 1 Trial Explained: Semaglutide 2.4 mg for Obesity in 2 Minutes
<p>Can once-weekly semaglutide produce meaningful weight loss in adults with obesity?</p><p>In this 2-minute evidence brief, we break down the STEP 1 trial, a randomized double-blind clinical trial published in the New England Journal of Medicine in 2021. The study tested semaglutide 2.4 mg once weekly versus placebo, both with lifestyle intervention, in adults with overweight or obesity but without diabetes.</p><p><br></p><p>Covered in this video:</p><ul><li>Why the STEP 1 trial was done</li><li>How the trial was conducted</li><li>Main weight loss results</li><li>Safety and gastrointestinal side effects</li><li>Key clinical takeaway</li><li><br></li></ul><p>Main result: average body weight decreased by 14.9% with semaglutide versus 2.4% with placebo over 68 weeks.</p><p><br></p><p>Citation:</p><p>Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.</p><p>PMID: 33567185</p><p>DOI: 10.1056/NEJMoa2032183</p><p><br></p><p>This video is for medical education only and does not replace clinical judgment or individual medical advice.</p><p><br></p><p><br></p><p>#Semaglutide #STEP1Trial #ObesityMedicine #GLP1 #MedicalEducation</p><p><br></p><p>semaglutide, STEP 1 trial, semaglutide obesity, semaglutide weight loss, Wegovy, GLP-1 receptor agonist, obesity treatment, obesity medicine, clinical trial explained, randomized controlled trial, RCT, NEJM, weight loss medication, semaglutide 2.4 mg, evidence based medicine, medical education, endocrinology, hormone insight, GLP-1 weight loss, obesity pharmacotherapy</p>
June 27, 2026
Jun 27, 2026: This Week in Diabetes & Endocrinology -- The triple agonist arrives, and the bar moves
<p>This week on Hormone Insight: the fallout from the ADA 2026 Scientific Sessions, where retatrutide — a triple GIP/GLP-1/glucagon agonist — delivered nearly 2 points of A1C and about 15% weight loss in type 2 diabetes (TRANSCEND-T2D-1). Plus CagriSema vs semaglutide head-to-head, finerenone in chronic kidney disease without diabetes, the new ADA/EASD type 1 diabetes consensus, and a Hormone Classic revisit of SUSTAIN-6 — the outcome bar every new drug still has to clear.</p><p><br></p><p>Segments:</p><p>• Trial of the Week — Retatrutide in type 2 diabetes (TRANSCEND-T2D-1, The Lancet)</p><p>• Quick Hit 1 — CagriSema vs semaglutide (REIMAGINE 2, Lancet Diabetes & Endocrinology)</p><p>• Quick Hit 2 — Finerenone in CKD without diabetes (FIND-CKD, NEJM)</p><p>• Guideline & FDA Watch — ADA/EASD type 1 diabetes in adults: 2026 consensus update</p><p>• Hormone Classic — SUSTAIN-6 (semaglutide cardiovascular outcomes, 2016)</p><p><br></p><p>⏱ Chapters</p><p>00:00 Cold open</p><p>00:38 Welcome & disclaimer</p><p>01:02 This week</p><p>01:47 Trial of the Week — Retatrutide (TRANSCEND-T2D-1)</p><p>03:51 The Appraisal</p><p>04:59 Bottom line — retatrutide</p><p>05:29 Quick Hit 1 — CagriSema vs semaglutide</p><p>06:54 Quick Hit 2 — Finerenone in CKD without diabetes</p><p>08:04 Guideline & FDA Watch — ADA/EASD type 1 diabetes</p><p>09:20 Hormone Classic — SUSTAIN-6</p><p>10:40 The Bottom Line</p><p>11:23 Sign-off</p><p><br></p><p> References & written summary: hormoneinsight.com/twide-2026-06-27</p><p>For healthcare professionals. Educational, not individual medical advice.</p><p>Subscribe for a new episode every Saturday. #diabetes #endocrinology #GLP1</p>
June 20, 2026
An Oral GLP-1 That Works: ATTAIN-2 and the 2026 ADA Standards | This Week in Diabetes & Endocrinology
<p>This week on This Week in Diabetes & Endocrinology, from Hormone Insight: the</p><p>first large phase 3 trial of an oral GLP-1, orforglipron, in adults with type 2</p><p>diabetes and obesity (ATTAIN-2, Lancet). The headline is not the size of the</p><p>weight loss. It is the word oral.</p><p><br></p><p>Also this week:</p><p>- A 112,000-patient ACP network meta-analysis that keeps semaglutide and</p><p> tirzepatide on top for both weight loss and cardiovascular outcomes</p><p>- A provocative real-world comparison of bariatric surgery versus semaglutide</p><p> in fatty liver disease</p><p>- The 2026 ADA Standards of Care, which make cardiovascular and kidney</p><p> protection a co-primary goal alongside A1C</p><p>- A Hormone Classic revisit of UKPDS that explains why that shift had to happen</p><p><br></p><p>One question runs through all of it: does this change Monday clinic?</p><p><br></p><p>Chapters</p><p>00:00 Cold open</p><p>00:42 This week</p><p>01:13 Trial of the Week: orforglipron (ATTAIN-2)</p><p>04:29 Quick Hit: ACP weight-loss drug meta-analysis</p><p>05:21 Quick Hit: surgery vs semaglutide (MASLD)</p><p>06:21 Guideline & FDA Watch: 2026 ADA Standards</p><p>07:27 Hormone Classics: UKPDS</p><p>08:26 The Bottom Line</p><p>08:57 Sign-off</p><p><br></p><p>References and written summary: hormoneinsight.com/[slug]</p><p><br></p><p>For healthcare professionals. Educational, not individual medical advice.</p><p>Subscribe for a new episode every Saturday.</p><p><br></p><p>#diabetes #endocrinology #GLP1 #obesity #ADA2026</p>
15 total episodes available
Deep-dive analytics for Hormone Insight
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Hormone Insight?
<p>Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.